Teicoplanin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Teicoplanin: From Gram-Positive Bacterial Infections to Bacterial Arthritis
One-Sentence Summary
Teicoplanin is a glycopeptide antibiotic long used to treat serious gram-positive bacterial infections (bacteremia, endocarditis, skin/soft-tissue and bone-joint infections). The TxGNN model predicts it may also be effective for Bacterial Arthritis, a prediction already substantially supported by 20 publications describing real-world use in septic/bone-joint infections, though no registered clinical trials exist for this specific indication and the drug is currently not marketed in Denmark.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the available Danish regulatory data (drug not marketed); literature describes established use in serious gram-positive bacterial infections |
| Predicted New Indication | Bacterial Arthritis |
| TxGNN Prediction Score | 94.25% |
| Evidence Level | L3 (systematic review/meta-analysis and observational studies; no registered clinical trials) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, Teicoplanin is a glycopeptide-class antibiotic active against gram-positive bacteria (including MRSA); its efficacy in serious gram-positive infections such as bacteremia, endocarditis, and skin/soft-tissue infections is well established in the literature.
Bacterial (septic) arthritis is most commonly caused by Staphylococcus aureus and other gram-positive organisms — the same pathogen spectrum teicoplanin already targets. Several of the publications retrieved for this candidate go beyond a purely computational hypothesis: they describe teicoplanin dosing regimens specifically for septic arthritis (e.g., 12 mg/kg/day, higher than the standard maintenance dose), and multiple studies report clinical outcomes in patients with pyogenic/septic arthritis treated with teicoplanin. This suggests the “new indication” reflects an already-recognized, if not formally registered, clinical use rather than a purely novel mechanistic extrapolation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8351549 | 1993 | Clinical trial | Southern Medical Journal | Community-based trial of once-daily teicoplanin (avg. 10.1 mg/kg) in 66 patients with gram-positive bone/joint infections including septic arthritis |
| 1381644 | 1992 | Clinical trial (cooperative study) | Eur J Surg Suppl | Teicoplanin Bone and Joint Cooperative Study Group (USA): 90/98 patients evaluated, including acute/chronic osteomyelitis |
| 2952062 | 1987 | Clinical trial | Antimicrob Agents Chemother | 19 patients with serious gram-positive infections incl. pyogenic arthritis; 8/13 evaluable cases clinically cured |
| 12481488 | 2002 | Retrospective study | Medicina | 89 episodes of MRSA bone/joint infections, including 10 septic arthritis cases; efficacy assessed by dosing schedule |
| 27809799 | 2016 | Retrospective cohort | BMC Infectious Diseases | Teicoplanin-based therapy (incl. subcutaneous route) in S. aureus bone and joint infection |
| 17825421 | 2007 | Cohort study | The Journal of Infection | Trough teicoplanin levels in musculoskeletal infection; standard doses may be subtherapeutic |
| 2140111 | 1990 | Clinical trial | J Antimicrob Chemother | 33 patients with bone/soft-tissue infections incl. 3 septic arthritis cases treated with teicoplanin |
| 9474479 | 1997 | Review | Drugs | Reviews anti-gram-positive agents; specifies higher teicoplanin dose (12 mg/kg/day) for septic arthritis |
| 11131961 | 2000 | Review | Journal of Chemotherapy | Reviews teicoplanin dosing across serious infections including bone and joint infections |
| 30876673 | 2019 | Retrospective cohort | Enferm Infecc Microbiol Clin | Dual teicoplanin + cefazolin prophylaxis to prevent prosthetic joint infection |
Denmark Market Information
Teicoplanin currently has no marketing authorisation on record in Denmark (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The literature base (L3: retrospective/cohort studies and reviews, no registered RCTs) offers reasonable mechanistic and real-world support, but the drug is not currently marketed in Denmark and a Blocking data gap exists — Danish/EU product-label warnings and contraindications are unavailable, which prevents the mandatory initial safety (S1) evaluation.
To proceed, the following is needed:
- Official SmPC/label warnings and contraindications (Blocking gap)
- Detailed mechanism of action data from DrugBank or equivalent source
- Confirmation of any EU/EMA marketing authorisation pathway applicable to Denmark
- Drug-drug interaction data (currently not found)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.